Humana Inc. logo HUM - Humana Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 17
HOLD 26
SELL 1
STRONG
SELL
0
| PRICE TARGET: $418.53 DETAILS
HIGH: $513.00
LOW: $300.00
MEDIAN: $415.00
CONSENSUS: $418.53
UPSIDE: 4.63%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Strong
Trading 60.0% above fair value
Current Price $400.02
Bear Case $200.00 50.0% downside ($200.00 - $400.02) / $400.02 = -50.0% $20.00 × 10x P/E
Fair Value $250.00 37.5% downside ($250.00 - $400.02) / $400.02 = -37.5% $20.00 × 12x P/E
Bull Case $300.00 25.0% downside ($300.00 - $400.02) / $400.02 = -25.0% $20.00 × 15x P/E

Adjust Assumptions

12.5x
20.0$

Key Value Driver

Normalized P/E multiple (12x base case)

Implied Market Multiple 20.0x

Plain-Language Summary

Applying a 12x P/E to adjusted EPS of $20.00, the base-case value is $250.00 per share. DDM cross-check: $71.87.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (44 analysts) $418.53
Analyst Range $300.00 – $513.00
Divergence from AlphaVal 40%

Warnings

The company's reported profits differ from official accounting profits by 103%. Check what costs are being left out of the adjusted number.
Dividend-based valuation: $71.87 (below our primary estimate by 71%). Large gaps may signal the dividend doesn't reflect full earning power.
Wall Street's average price target is $418.53 (from 44 analysts). Our estimate is 40% below the consensus -- consider that gap carefully.

Key Risks

  • Growth DCF inappropriate — terminal value assumptions dominate
  • EV/EBITDA misleading for regulated businesses where capex is mandated
  • Regulatory risk is a fat tail not visible in normal multiples